The Global Cholera Vaccines Oral Live Market was valued at USD 85 million in 2023 and is projected to reach USD 156.27 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.00% during the forecast period (2023–2032). This growth is driven by increasing cholera outbreaks in endemic regions, expanded government vaccination programs, and the proven efficacy advantages of oral live vaccines over traditional injectable formats.
As global health organizations ramp up cholera prevention efforts, pharmaceutical innovators are scaling production of WHO-prequalified oral cholera vaccines. Here we examine the Top 10 Companies in the Cholera Vaccines Oral Live Market—pioneers ensuring equitable access to these life-saving immunization solutions worldwide.
Download FREE Sample Report: Cholera Vaccines Oral Live Market – View in Detailed Research Report
🔟 1. PaxVax (Emergent BioSolutions)
Headquarters: Redwood City, California, USA
Key Offering: Vaxchora® (CVD 103-HgR)
PaxVax developed the only FDA-approved single-dose oral cholera vaccine, now commercialized by Emergent BioSolutions. Vaxchora® demonstrates 90% efficacy within 10 days and remains the gold standard for travelers to endemic areas.
Innovation Highlights:
- Lyophilized formulation enhancing stability in tropical climates
- Proven cross-protection against enterotoxigenic E. coli (ETEC)
- Available in major markets including US, EU, and Canada
9️⃣ 2. Sanofi Pasteur
Headquarters: Lyon, France
Key Offering: Dukoral®
Sanofi’s bivalent Dukoral vaccine offers dual protection against cholera and ETEC, making it invaluable for travelers and outbreak response teams. Its two-dose regimen provides 85% protection for six months.
Global Reach:
- Licensed in 60+ countries
- Core component of WHO’s emergency stockpile
- Thailand manufacturing facility supplies Asia-Pacific region
8️⃣ 3. Valneva SE
Headquarters: Saint-Herblain, France
Key Offering: Vaxchora® distribution rights (select markets)
Valneva has fortified its travel vaccine portfolio through strategic licensing agreements, bringing Vaxchora® to European and Asian markets where cholera remains endemic.
Strategic Position:
- Exclusive EU commercialization rights for Vaxchora®
- Developing thermostable formulations for tropical deployment
- Partnered with Gavi on cholera prevention initiatives
Download FREE Sample Report: Cholera Vaccines Oral Live Market – View in Detailed Research Report
7️⃣ 4. EuBiologics Co., Ltd.
Headquarters: Seoul, South Korea
Key Offering: Euvichol® and Euvichol-Plus®
As the world’s largest cholera vaccine supplier to WHO, EuBiologics delivers affordable solutions through innovative manufacturing and packaging technologies.
Production Capacity:
- 80 million annual doses produced at GMP facilities
- Plastic tube delivery system reduces cold chain requirements
- Prequalified by WHO for UN procurement programs
6️⃣ 5. Shanghai United Cell Biotechnology
Headquarters: Shanghai, China
Key Offering: rBS-WC oral cholera vaccine
This Chinese innovator specializes in thermostable formulations ideal for Asia’s tropical climates, with growing exports to developing nations through international partnerships.
Market Position:
- Approved in 15+ Asian and African countries
- Bulk supplier to national immunization programs
- $0.50-$1.00 per dose pricing for public health markets
5️⃣ 6. Vabiotech
Headquarters: Hanoi, Vietnam
Key Offering: mORC-Vax™
Vietnam’s national vaccine producer developed this WHO-prequalified oral vaccine specifically for Southeast Asian cholera strains and distribution conditions.
Regional Expertise:
- Optimized for regional serogroup prevalence
- Integrated into Vietnam’s EPI schedule
- Three-year shelf life in tropical storage conditions
4️⃣ 7. Shantha Biotechnics (Sanofi)
Headquarters: Hyderabad, India
Key Offering: Shanchol™
Sanofi’s Indian subsidiary produces this WHO-prequalified vaccine that has immunized millions through GAVI and UNICEF programs in developing nations.
Public Health Impact:
- $1.85 per dose for humanitarian procurement
- 65% efficacy maintained over 5 years
- Distributed 50+ million doses since 2009
3️⃣ 8. Takeda Pharmaceutical
Headquarters: Tokyo, Japan
Key Offering: Vaxchora® Asia-Pacific rights
Takeda applies its vaccine commercialization expertise to expand access across Asia-Pacific, where 60% of global cholera cases occur.
Regional Strategy:
- Localized packaging for tropical climates
- Partnerships with travel medicine providers
- Outbreak response collaborations with ministries of health
2️⃣ 9. Bharat Biotech
Headquarters: Hyderabad, India
Key Offering: Novel OCV pipeline
India’s vaccine powerhouse is advancing next-generation oral cholera vaccines with extended thermostability and longer-lasting immunity.
Development Focus:
- Single-dose formulations in Phase II trials
- New adjuvant technologies in development
- 200+ million dose annual production capability
Read Full Report: Cholera Vaccines Oral Live Market – View in Detailed Research Report
1️⃣ 10. Biological E. Limited
Headquarters: Hyderabad, India
Key Offering: BE-CholVac (in development)
Partnering with IVI, this established vaccine manufacturer is developing an ultra-low-cost oral cholera vaccine for mass immunization in endemic regions.
Pipeline Promise:
- Target sub-$0.50 per dose pricing
- No cold chain requirements
- Palatable formulation for pediatric use
🌍 Market Outlook: The Next Era of Cholera Prevention
The oral cholera vaccine market is undergoing a revolutionary transformation, with innovations targeting the unique challenges of endemic regions and outbreak response.
📈 Key Developments Reshaping the Industry:
- Accelerated WHO prequalification pathways for outbreak-responsive vaccines
- Novel encapsulation technologies extending shelf life without refrigeration
- Combination vaccines protecting against multiple enteric diseases
- Artificial intelligence optimizing outbreak prediction and vaccine deployment
- Digital platforms enhancing vaccination tracking in remote communities
The companies profiled represent the vanguard of cholera prevention—blending scientific excellence with global health equity to eliminate this ancient scourge.
Read Full Report: Cholera Vaccines Oral Live Market – View in Detailed Research Report